Pinealon is a synthetic Glu‑Asp‑Arg tripeptide that users most often take for sleep and circadian regulation, and they commonly report changes in sleep and dreaming (both positive and negative), while a smaller group uses it for cognitive enhancement or neuroprotection. The community typically doses around 500 µg daily (with a wide 100 µg–10 mg range), and clinician sources often recommend 1 mg subcutaneously each day, neither specifying timing or cycling. The main caveat is that the off‑label evidence base is thinner than the conversation implies, with most exploratory uses lacking posted results.
Data last updated
Measured on 5 of 6 axes
Evidence shape
According to the available literature, Pinealon exhibits limited, exploratory human evidence for treatment studies, supported by four published studies. The evidence breadth covers two indications — one thin/exploratory human indication (treatment studies, represented by four trials) and one animal‑only indication (preclinical/mechanistic research) — while the quality assessment notes that no completed trials have been reported. With zero registered trials indicated in the depth data and no completed trials recorded in the quality data, the absence of formal clinical evaluation serves as a clear signal of the current evidence gap.
Efficacy signal
Completed studies are present, but primary-endpoint pass/fail classification is not yet clean enough to score. These are the currently projected indication-level signals.
Treatment studies
4 studies
No completed study rows are available for endpoint scoring yet.
Human evidence
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Grouped from 2 published human studies — weighted by study count, not incidence (the papers report no rates).
Anecdotal side effects
price offers can be sorted by column
How Pinealon is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
In the research trials tier, Pinealon was given subcutaneously twice daily, yet the four human studies identified did not provide a reliably extractable dose amount.
In clinician practice, Pinealon is used at a fixed 1 mg dose, administered subcutaneously on a daily basis; the dose range is 1 mg to 1 mg, and no weight‑based dosing or cycling schedule is reported.
Most community users report taking Pinealon daily, typically around 1 mg, while a larger group did not specify a schedule and commonly use 500 mcg; a few dose twice daily.